Dipyrone (metamizole), overrated risks?
References
1. Gómez-Duarte OG. Is it time to restrict the clinical use of dipyrone? Colombian Journal of Anesthesiology 2019;47:81-83.
2. Ziesenitz VC, Erb TO, Trachsel D, et al. Safety of dipyrone (metamizole) in children-what’s the risk of agranulocytosis? Paediatr Anaesth 2018;28:186-187.
3. De Leeuw TG, Dirckx M, De Wildt SN. Reply to Ziesenitz, Victoria; Erb Thomas; Trachsel, Daniel; Van den Anker Johannes, regarding their comment “Safety of dipyrone (metamizole) in children- what’s the risk of agranulocytosis?”. Paediatr Anaesth 2018;28: 305-306.
4. Kotter T, Da Costa BR, Fassler M, et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One 2015;10:e0122918.
5. Gaertner J, Stamer UM, Remi C, et al. Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. Palliat Med 2017;31:26-34.
6. Konijnenbelt-Peters J, Van der Heijden C, Ekhart C, et al. Metamizole (Dipyrone) as an alternative agent in postoperative analgesia in patients with contraindications for nonsteroidal anti-inflammatory drugs. Pain Pract 2017;17:402-408.
7. AndradeSE,MartinezC,WalkerAM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998;51:1357-1365.
8. Shah RR. Metamizole (dipyrone)-induced agranulocytosis: does the risk vary according to ethnicity? J Clin Pharm Ther 2019;44: 129-133.
9. Vuik FE, Koehestanie P, Herbers AH, et al. Chronic use of metamizole: not so safe after all? Neth J Med 2017;75:81-83.
10. Maluf E, Hamerschlak N, Cavalcanti AB, et al. Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. Haematologica 2009;94:1220-1226.
11. Huber M, Andersohn F, Sarganas G, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2015;71:219-227.
12. Stammschulte T, Ludwig WD, Muhlbauer B, et al. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol 2015;71: 1129-1138.
13. Andrade S, Bartels DB, Lange R, et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther 2016;41: 459-477.
14. International Collaborative Study of Severe Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf 2003;12:195-202.
15. Laxenaire MC, Mertes PM. Anaphylaxis during anaesthesia. Results of a two-year survey in France. Br J Anaesth 2001;87: 549-558.
16. Grupo de Programas Especiales-Farmacovigilancia de la Dirección de Medicamentos y Productos Biológicos del Instituto Nacional de Medicamentos y Alimentos (INVIMA). Dipirona (Metamizol) y su relación con discrasias sanguíneas. FarmaSeguridad. [Internet. Bogotá: Invima; 2015 [Cited 13 Sep 2019. Available at: https://www.invima.gov.co/documents/20143/462902/Farmaseguridad+Vol+4+N-2.pdf/24cbc325-71d7-a48c-a1db-f4d974312e36.
17. Sanofi-Aventis Farmacéutica Ltda. Novalgina(r) (dipirona mono-idratada) [Internet. Agência nacional de vigilância sanitária (Brazil); 2006 [cited 2019 Sep 12. Available at: Disponible en: http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=24854142016&pIdAnexo=4018378.
18. Drawer S.A. Dipirona DRAWER Dipirona 1 g inyectable - Prospecto [Internet. Laboratorio Drawer (Argentina); [cited 2019 Sep 12; Available at: http://drawer.com.ar/admin/resources/files/productos/6/PROSPECTO_DIPIRONA.pdf.
19. Sanofi Argentina. NOVALGINA* DIPIRONA; 50 mg/ml Jarave - vía oral. Sanofi-Aventis Argentina S.A. (Argentina); 2017 [cited 2019 Sep 12; Available at: https://www.sanofi.com.ar/-/media/Project/One-Sanofi-Web/Websites/Latin-America/Sanofi-AR/Home/Productos/ANALGESIA/NOVALGINA-jarabe-Prospecto-paciente.pdf?la=es&hash=72AD6E3D738A1B9EDBA0E2A2F898663F7F92E620.
2. Ziesenitz VC, Erb TO, Trachsel D, et al. Safety of dipyrone (metamizole) in children-what’s the risk of agranulocytosis? Paediatr Anaesth 2018;28:186-187.
3. De Leeuw TG, Dirckx M, De Wildt SN. Reply to Ziesenitz, Victoria; Erb Thomas; Trachsel, Daniel; Van den Anker Johannes, regarding their comment “Safety of dipyrone (metamizole) in children- what’s the risk of agranulocytosis?”. Paediatr Anaesth 2018;28: 305-306.
4. Kotter T, Da Costa BR, Fassler M, et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One 2015;10:e0122918.
5. Gaertner J, Stamer UM, Remi C, et al. Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. Palliat Med 2017;31:26-34.
6. Konijnenbelt-Peters J, Van der Heijden C, Ekhart C, et al. Metamizole (Dipyrone) as an alternative agent in postoperative analgesia in patients with contraindications for nonsteroidal anti-inflammatory drugs. Pain Pract 2017;17:402-408.
7. AndradeSE,MartinezC,WalkerAM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998;51:1357-1365.
8. Shah RR. Metamizole (dipyrone)-induced agranulocytosis: does the risk vary according to ethnicity? J Clin Pharm Ther 2019;44: 129-133.
9. Vuik FE, Koehestanie P, Herbers AH, et al. Chronic use of metamizole: not so safe after all? Neth J Med 2017;75:81-83.
10. Maluf E, Hamerschlak N, Cavalcanti AB, et al. Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. Haematologica 2009;94:1220-1226.
11. Huber M, Andersohn F, Sarganas G, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2015;71:219-227.
12. Stammschulte T, Ludwig WD, Muhlbauer B, et al. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol 2015;71: 1129-1138.
13. Andrade S, Bartels DB, Lange R, et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther 2016;41: 459-477.
14. International Collaborative Study of Severe Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf 2003;12:195-202.
15. Laxenaire MC, Mertes PM. Anaphylaxis during anaesthesia. Results of a two-year survey in France. Br J Anaesth 2001;87: 549-558.
16. Grupo de Programas Especiales-Farmacovigilancia de la Dirección de Medicamentos y Productos Biológicos del Instituto Nacional de Medicamentos y Alimentos (INVIMA). Dipirona (Metamizol) y su relación con discrasias sanguíneas. FarmaSeguridad. [Internet. Bogotá: Invima; 2015 [Cited 13 Sep 2019. Available at: https://www.invima.gov.co/documents/20143/462902/Farmaseguridad+Vol+4+N-2.pdf/24cbc325-71d7-a48c-a1db-f4d974312e36.
17. Sanofi-Aventis Farmacéutica Ltda. Novalgina(r) (dipirona mono-idratada) [Internet. Agência nacional de vigilância sanitária (Brazil); 2006 [cited 2019 Sep 12. Available at: Disponible en: http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=24854142016&pIdAnexo=4018378.
18. Drawer S.A. Dipirona DRAWER Dipirona 1 g inyectable - Prospecto [Internet. Laboratorio Drawer (Argentina); [cited 2019 Sep 12; Available at: http://drawer.com.ar/admin/resources/files/productos/6/PROSPECTO_DIPIRONA.pdf.
19. Sanofi Argentina. NOVALGINA* DIPIRONA; 50 mg/ml Jarave - vía oral. Sanofi-Aventis Argentina S.A. (Argentina); 2017 [cited 2019 Sep 12; Available at: https://www.sanofi.com.ar/-/media/Project/One-Sanofi-Web/Websites/Latin-America/Sanofi-AR/Home/Productos/ANALGESIA/NOVALGINA-jarabe-Prospecto-paciente.pdf?la=es&hash=72AD6E3D738A1B9EDBA0E2A2F898663F7F92E620.
How to Cite
1.
Giraldo-Gutiérrez DS, Amézquita-Trujillo Álvaro. Dipyrone (metamizole), overrated risks?. Colomb. J. Anesthesiol. [Internet]. 2019 Oct. 1 [cited 2024 Apr. 19];47(4):257-9. Available from: https://www.revcolanest.com.co/index.php/rca/article/view/35
Downloads
Download data is not yet available.
Published
2019-10-01
How to Cite
1.
Giraldo-Gutiérrez DS, Amézquita-Trujillo Álvaro. Dipyrone (metamizole), overrated risks?. Colomb. J. Anesthesiol. [Internet]. 2019 Oct. 1 [cited 2024 Apr. 19];47(4):257-9. Available from: https://www.revcolanest.com.co/index.php/rca/article/view/35
Issue
Section
Letter to the Editor
Altmetric
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
